Mantle Cell Lymphoma

Jia Ruan, MD, PhD, discusses the evolving armamentarium ​in mantle cell lymphoma.

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Caron Jacobson, MD, discusses the approval of brexucabtagene autoleucel in mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on patients with mantle cell lymphoma.

Brian T. Hill, MD, PhD, reflects on how the approval of CAR T-cell therapy has impacted clinical practice for his patients with MCL, ongoing research with practice-changing implications, and how MCL treatment has evolved during the coronavirus disease 2019 pandemic.

Brian T. Hill, MD, PhD, discusses the FDA approval of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma.

Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for KTE-X19 as a treatment in adult patients with relapsed/refractory mantle cell lymphoma who previously received 2 or more lines of systemic therapy, including a BTK inhibitor.

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Carlo Visco, MD, discusses the results from the MANTLE-FIRST trial and the next steps for the research.

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

Patients with mantle cell lymphoma who have high-risk biology, including blastoid variant, a Ki-67 score of at least 30%, or high p53 expression, had a significantly shorter failure-free and overall survival.

Carlo Visco, MD, discusses the next steps for the international, retrospective MANTLE-FIRST trial in patients with relapsed/refractory mantle cell lymphoma.

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Carlo Visco, MD, discusses the utility of bendamustine-based regimens in mantle cell lymphoma.

Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.